{"filings":[{"id":890361,"accession_number":"0001104659-26-071027","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2026-06-05T21:00:31+00:00","items":["5.02"],"status":"ready","headline":"Petros Pharmaceuticals grants 7M restricted shares to Chairman, two directors, and President","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Aggregate 7,000,000 restricted shares granted to Joshua Silverman (Chairman), Bruce Bernstein, Fady Boctor, and Wayne Walker.","Silverman receives 4,375,000 shares; Bernstein 1,875,000; Boctor and Walker 375,000 each.","50% vested immediately on June 5, 2026; remaining 50% vests on six-month anniversary.","Issued outside the Amended and Restated 2020 Omnibus Incentive Compensation Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108963,"accession_number":"0001104659-26-000236","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2026-01-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Petros Pharmaceuticals grants 7.25M RSUs to executives and directors; 50% vested immediately","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Joshua Silverman (Chairman) receives 4,375,000 RSUs; Bruce Bernstein 1,875,000; Fady Boctor 500,000; Wayne Walker 500,000.","50% of each RSU grant vested on Jan 2, 2026; remaining 50% vests at six-month anniversary subject to continued service.","Grants issued outside the company's 2020 Omnibus Incentive Compensation Plan.","Total RSUs represent approximately 14% of current outstanding shares (est.) based on prior filings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125414,"accession_number":"0001104659-25-108552","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Nasdaq notifies Petros Pharmaceuticals of common stock delisting effective Nov 7, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Petros on Nov 3, 2025, of intention to delist common stock on Nov 7, 2025.","Stock suspended from Nasdaq Capital Market on May 22, 2025; trading on OTCID since July 1, 2025.","Nasdaq to file Form 25 to deregister stock under Section 12(b); delisting effective 10 days later.","Common stock continues trading on OTCID symbol PTPI without disruption; SEC reporting obligations remain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142149,"accession_number":"0001104659-25-087887","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2025-09-05T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Petros Pharmaceuticals dismisses CBIZ CPAs, appoints HTL International as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee approved dismissal of CBIZ CPAs as auditor effective Aug 29, 2025.","CBIZ CPAs had been engaged on April 5, 2025 after acquiring Marcum's attest business.","No disagreements with CBIZ CPAs; only reportable event was previously disclosed material weakness in internal controls.","Engaged HTL International as new independent auditor for fiscal year ending Dec 31, 2025, effective Aug 29.","No prior consultations with HTL regarding accounting or auditing matters."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160137,"accession_number":"0001104659-25-061230","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Petros Pharmaceuticals assigns subsidiary assets (Metuchen, Timm, Pos-T-Vac) to creditor trust","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Effective June 16, 2025, Petros assigned all assets of subsidiaries Metuchen, Timm Medical, and Pos-T-Vac to a third-party fiduciary for benefit of creditors.","The Vivus License Agreement for Stendra® was terminated March 31, 2025; Petros lost all rights to Stendra in the Licensed Territory.","Pro forma balance sheet shows stockholders' equity of $8.0M as of March 31, 2025, reflecting deconsolidation, warrant exercises, and redemptions.","Subsidiaries' operations classified as discontinued; deconsolidation from Petros' balance sheet expected in Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160136,"accession_number":"0001104659-25-051336","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Petros Pharma receives Nasdaq delisting notice; trading to move to OTC Markets","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Delisting due to failing minimum equity, bid price ($1.00), and public interest concerns from Feb 2025 offering.","Trading suspended on Nasdaq at open May 22, 2025; expected to trade on OTC Markets under PTPI.","Company has 15 days to appeal to Nasdaq Listing Council; appeal stays Form 25 but not suspension.","No assurance that Listing Council will grant continued listing on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160135,"accession_number":"0001104659-25-044240","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2025-05-02T23:59:59+00:00","items":["3.01","3.03","5.03","9.01"],"status":"ready","headline":"Petros gets additional Nasdaq delisting notice for Feb 2025 offering; completes 1-for-25 reverse split","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Petros on April 28 of public interest concerns regarding its February 19, 2025 public offering as a new delisting basis under Rule 5810(d).","Company intends to address concerns before a Nasdaq Hearings Panel; delisting actions are stayed pending the hearing.","1-for-25 reverse stock split effective 4:05 pm ET April 30, 2025; split-adjusted trading began May 1, 2025, under same symbol PTPI.","No fractional shares issued; authorized shares remain 7 billion; proportionate adjustments made to options and equity plan.","New CUSIP number is 71678J308; the reverse split does not immediately affect trading."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160134,"accession_number":"0001104659-25-034283","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2025-04-11T23:59:59+00:00","items":["3.01","3.03","5.03","5.02","5.07","9.01"],"status":"ready","headline":"Petros receives Nasdaq equity deficiency delisting notice; shareholders approve massive share increase and reverse split","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq notified Petros on Apr 8 it fails $2.5M minimum stockholders' equity requirement, adding to existing bid price deficiency.","All delisting actions stayed pending hearing before Nasdaq Hearings Panel; company intends to address concerns.","At special meeting Apr 10, stockholders approved increasing authorized common shares from 250M to 7B.","Also approved reverse stock split at ratio of 1-for-250 to 1-for-500, at Board's discretion.","Approved increase in incentive plan shares by 1B to 1,002,760,000, and issuance of shares underlying Series Warrants from Feb 2025 offering (approx 1.06B shares)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160133,"accession_number":"0001104659-25-033391","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2025-04-09T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Petros Pharmaceuticals terminates Marcum as auditor, engages CBIZ; prior reports include going concern","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company terminated Marcum LLP as auditor on April 5, 2025, and engaged CBIZ CPAs P.C. as new independent auditor for FY 2025.","No disagreements or reportable events except a material weakness in internal controls over financial reporting disclosed in 2024 10-K.","Marcum's reports for FY 2023 and 2024 included an explanatory paragraph about substantial doubt as a going concern.","Marcum provided a letter to SEC dated April 9, 2025, agreeing with the company's statements (Exhibit 16.1 filed)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178450,"accession_number":"0001104659-25-016181","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2025-02-21T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Petros Pharmaceuticals Prices $9.6 Million Public Offering of Common Stock and Warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Petros Pharmaceuticals entered securities purchase agreement for 13,950,012 units and 26,049,988 pre-funded units at $0.24 and $0.2399 per unit.","Offering closed on February 19, 2025, with gross proceeds of approximately $9.6 million.","Each unit includes one share (or pre-funded warrant), one Series A warrant (0.25 share) and one Series B warrant (1 share) at $0.48 exercise price.","Warrants exercisable only upon stockholder approval; pre-funded warrants immediately exercisable at $0.0001 per share.","Company granted 1,000,000, 300,000, 150,000, 450,000, 150,000, and 150,000 restricted shares to directors Silverman, Bernstein, Walker, Boctor, Arnold, and Weinstein."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178449,"accession_number":"0001104659-25-005980","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2025-01-24T23:59:59+00:00","items":["1.01","3.03","5.03","9.01"],"status":"ready","headline":"Petros Pharmaceuticals amends Series A Preferred; maturity extended to Feb 2025, $500k cash covenant added","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Extended maturity date of Series A Convertible Preferred Stock from prior date to February 15, 2025.","Deferred all unpaid accrued amounts under the Certificate of Designations to February 15, 2025.","Company must maintain at least $500,000 in unrestricted cash from January 15 to February 15, 2025.","Amended restrictive covenant to allow changes in sales strategy for Stendra avanafil and OTC switch platform.","Required holders waived any breach from failure to pay outstanding amounts as of January 23, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195118,"accession_number":"0001104659-24-128984","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2024-12-16T23:59:59+00:00","items":["2.04","9.01"],"status":"ready","headline":"Petros subsidiary defaults on $7.25M note; Vivus forecloses on collateral for $2M partial satisfaction","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Metuchen failed to pay installment due Oct 1, 2024; all obligations accelerated.","Outstanding principal $7,246,634.90 plus interest $237,300.35 at default rate of 9%.","Secured party Vivus LLC proposed acceptance of foreclosed collateral in partial satisfaction of $2M obligations.","Metuchen agreed to foreclosure on Dec 13, 2024; remaining obligations continue.","Collateral excludes a Specified License Agreement; no other terms disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195117,"accession_number":"0001104659-24-121603","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2024-11-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Petros Pharma stockholders OK reverse stock split up to 1:25","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Directors Silverman, Bernstein, Walker elected to one-year terms.","Reverse stock split (range 1:2 to 1:25, Board discretion) approved; For 2,949,518, Against 1,350,781.","Marcum LLP ratified as independent auditor for FY2024 with 3,984,099 for votes.","Advisory say-on-pay proposal passed with 1,433,687 for votes.","Adjournment proposal passed to allow further proxy solicitation if needed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195116,"accession_number":"0001104659-24-109893","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2024-10-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Petros Pharma reduces President Boctor's base salary to $280K, sets Dec 31 termination","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Base salary cut from $350K to $280K effective Oct 16, 2024.","Employment termination date set to Dec 31, 2024; at-will status continues.","Boctor now permitted to engage in other consulting/employment activities if no conflict.","Amendment approved by Director Josh Silverman."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195115,"accession_number":"0001104659-24-109575","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2024-10-17T23:59:59+00:00","items":["1.01","3.03","5.03","9.01"],"status":"ready","headline":"Petros Pharmaceuticals amends Series A Preferred to grant voting rights at $2.25 conversion price","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment grants Series A Preferred holders voting rights on as-converted basis at $2.25/share conversion price.","Certificate of Amendment filed with Delaware Secretary of State, effective October 11, 2024.","Required Holders (majority of outstanding preferred) agreed; no additional consideration paid to investors.","Amendment modifies terms from original July 2023 Securities Purchase Agreement; no other changes to transaction documents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195114,"accession_number":"0001104659-24-106322","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2024-10-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Two directors resign from Petros Pharmaceuticals board without disagreement","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Shulman resigned as director effective Oct 1, 2024; no disagreement cited.","Greg Bradley resigned as director effective Oct 2, 2024; no disagreement cited.","No replacements announced; remaining board composition unclear."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211396,"accession_number":"0001104659-24-101333","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2024-09-19T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"Petros Pharmaceuticals sets 2024 annual meeting for Nov 20; shareholder proposals due Sept 29","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual meeting scheduled for November 20, 2024; record date October 14, 2024.","Shareholder proposals under Rule 14a-8 must be received by September 29, 2024.","Director nominations and other business proposals also due September 29, 2024.","Meeting date changed by more than 30 days from 2023 anniversary, triggering new deadlines.","Universal proxy rule compliance notice must be provided by September 29, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248466,"accession_number":"0001104659-24-037906","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2024-03-22T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Petros enters waiver/amendment with investors covering Dec 2023 equity awards and warrant terms","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Waives breach from Dec 21, 2023 issuance of 348,711 shares/options; deems them Excluded Securities.","Amends Section 4(c) of Warrants clarifying Black Scholes Value rights in Fundamental Transactions.","Waiver and Amendment effective as of December 31, 2023, entered March 21, 2024.","No additional consideration paid to investors; all holders of Preferred Stock and Warrants are party."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248465,"accession_number":"0001104659-24-003706","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2024-01-12T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Petros Pharmaceuticals dismisses EisnerAmper as auditor, appoints Marcum; cites material weaknesses","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit committee dismissed EisnerAmper as independent auditor on January 8, 2024; engaged Marcum effective immediately.","EisnerAmper's reports for FY2021 and FY2022 contained a going-concern paragraph due to net losses and negative cash flows.","Material weaknesses in internal control identified for FY2021, FY2022, and Q1-Q3 2023: insufficient monitoring, segregation of duties, IT access.","No disagreements with EisnerAmper on accounting principles or audit scope during the period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265970,"accession_number":"0001104659-23-130468","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2023-12-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Petros Pharma 2023 annual meeting: all director nominees elected, auditor ratified, say-on-pay passes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected directors John Shulman, Joshua Silverman, Bruce Bernstein, Gregory Bradley, Wayne Walker with over 88% of votes cast for each.","Ratified EisnerAmper as independent auditor for FY 2023: 1,181,138 for, 91,884 against, 2,869 abstain.","Advisory say-on-pay approved: 735,195 for, 30,435 against, 4,208 abstain; broker non-votes 506,053.","All proposals passed at December 29, 2023 Annual Meeting; no other matters voted on."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265969,"accession_number":"0001104659-23-130046","cik":1815903,"company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","form_type":"8-K","filed_at":"2023-12-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Petros Pharmaceuticals awards 49,645 shares and options to President Boctor, options to VP Arnold","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["One-time grant to President & CCO Fady Boctor: 49,645 common shares and options for 109,066 shares at $1.41.","50% of Boctor's options vested on grant; remaining vest based on 2023-2024 strategic goals.","One-time grant to VP Finance & CAO Mitchell Arnold: options for 20,000 shares at $1.41, fully vested.","Grants made under Amended and Restated 2020 Omnibus Incentive Compensation Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":258471.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}